NCT03853746View on ClinicalTrials.gov

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

March 1, 2024

Study Completion Date

July 1, 2024

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab

Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

lead

Johns Hopkins University

OTHER

NCT03853746 - Short-term B-cell Depletion in Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter